Regeneron has submitted a request to FDA for Emergency Use Authorization approval for the
REGN-COV2 investigational antibody combination for COVID-19.
REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2. The agent was recently used to treat President Donald Trump.
If an EUA is granted, the government has committed to making these doses available at no cost, and would be responsible for their distribution.
At this time, there are doses available for approximately 50,000 patients. Regeneron said it expects to have doses available for 300,000 patients in total within the next few months.
